Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review
- 31 July 2004
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (11), 1724-1730
- https://doi.org/10.1016/j.ejca.2004.03.026
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC)European Journal Of Cancer, 2003
- Quality assurance in radiotherapy: from radiation physics to patient- and trial-oriented control proceduresEuropean Journal Of Cancer, 2002
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Magnetic resonance imaging and histopathology of cerebral gliomasNeuroradiology, 1992
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomaJournal of Neurosurgery, 1989
- Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytomaInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study groupCancer, 1981
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980
- Assumptions in the radiotherapy of glioblastomaNeurology, 1980